denkapparat Operations GmbH Takes $713,000 Position in Exelixis, Inc. (NASDAQ:EXEL)

denkapparat Operations GmbH purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 21,410 shares of the biotechnology company’s stock, valued at approximately $713,000. Exelixis accounts for approximately 1.1% of denkapparat Operations GmbH’s portfolio, making the stock its 20th biggest position.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Exelixis in the fourth quarter valued at about $94,867,000. Allspring Global Investments Holdings LLC lifted its holdings in Exelixis by 82.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock valued at $52,884,000 after acquiring an additional 704,786 shares during the last quarter. Globeflex Capital L P grew its position in Exelixis by 203.8% in the fourth quarter. Globeflex Capital L P now owns 975,151 shares of the biotechnology company’s stock worth $32,473,000 after acquiring an additional 654,200 shares during the period. Caisse DE Depot ET Placement DU Quebec acquired a new stake in Exelixis during the third quarter worth $14,979,000. Finally, Raymond James Financial Inc. purchased a new stake in Exelixis in the fourth quarter valued at $17,046,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Trading Down 0.5 %

Shares of Exelixis stock opened at $36.84 on Friday. The company has a fifty day simple moving average of $35.70 and a 200-day simple moving average of $33.14. The stock has a market cap of $10.31 billion, a price-to-earnings ratio of 20.81, a PEG ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $40.02.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on EXEL. UBS Group increased their price target on Exelixis from $30.00 to $34.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. JMP Securities reissued a “market outperform” rating and issued a $41.00 price target on shares of Exelixis in a research note on Thursday, January 23rd. Guggenheim restated a “buy” rating and issued a $42.00 price objective on shares of Exelixis in a report on Wednesday, February 12th. Barclays boosted their target price on Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Finally, StockNews.com upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and a consensus price target of $37.59.

Insider Buying and Selling at Exelixis

In other news, Director Jack L. Wyszomierski sold 8,768 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $37.80, for a total value of $331,430.40. Following the transaction, the director now owns 356,605 shares of the company’s stock, valued at approximately $13,479,669. The trade was a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Patrick J. Haley sold 52,636 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.98, for a total value of $1,946,479.28. Following the sale, the executive vice president now directly owns 303,310 shares of the company’s stock, valued at approximately $11,216,403.80. This represents a 14.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 140,343 shares of company stock worth $5,177,234. 2.85% of the stock is owned by insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.